Miraculin protein production via plant tissue culture for sugarless sweetener applications

Overview

This solution offers a scalable production platform for miraculin, a naturally occurring protein that converts sour tastes into sweet perceptions. Miraculin, found in the tropical 'miracle berry' (Synsepalum dulcificum), has been known for centuries for its taste-modifying properties and represents a promising sugarless sweetener alternative. The technology leverages plant tissue culture combined with proprietary large-scale plastic bag bioreactors designed to overcome the capital and operating cost constraints that have historically prevented economic commercialization of plant-derived food and flavor ingredients.

Technical specifications

Key features:

• Plastic bag bioreactor system scaled beyond 100 liters with minimal instrumentation requirements
• Plant tissue culture platform suitable for homologous expression in the native Synsepalum dulcificum species
• Potential for non-GMO heterologous expression routes using native promoter sequences
• Process design optimized for moderate-value food and flavor production economics
• Compatibility with continuous operation, protein secretion, and cell immobilization strategies
• Addresses simple glycosylation requirements that preclude prokaryotic (bacterial) expression systems

Technical approach:

The platform addresses the fundamental challenge that traditional pharmaceutical-grade bioreactors are economically impractical for food-grade protein production due to extended processing times from comparatively slow plant tissue growth. The bioreactor design prioritizes low capital investment and operational simplicity while maintaining sufficient control for consistent protein production.

Technology readiness level

The underlying bioreactor technology has been developed, demonstrated, and patented at scales exceeding 100 liters. Miraculin protein was identified in 1968 and first expressed in tissue culture in 1997, with heterologous expression in plant culture patented in 2009. Recent publications through 2021 continue refining expression approaches but have not yet addressed economic feasibility. Future validation efforts include establishing Synsepalum dulcificum tissue cultures, evaluating quantification and bio-functionality assays, and assessing productivity scenarios across different bioreactor design and operation strategies.